IRRAS AB announced today that a healthcare team in Southern California is the first to use the company’s IRRAflow device on a U.S. patient with intracranial bleeding.
A University of California–Irvine (UCI) Medical Center team led by Dr. Sumeet Vadera successfully treated a patient who suffered a chronic subdural hematoma after a recent fall.
The IRRAflow device – FDA cleared last year – is meant to provide a safer, more effective treatment than traditional drainage devices. It uses a dual-lumen catheter to combine active irrigation with ongoing fluid drainage. It integrates aspiration, fluid irrigation and ICP monitoring into one system, with a proprietary software providing automated and tailored treatment.
“At UCI, we pride ourselves on providing our patients the latest in cutting-edge treatment options, and we can now provide the first active, therapeutic treatment to manage intracranial fluid with IRRAflow,” Vadera, an associate professor of neurological surgery at the UCI School of Medicine, said in a news release.
Since the FDA clearance for IRRAflow, Stockholm-based IRRAS has formed a customer service and shipping partnership with HealthLink Europe & International, hired territory managers, and created marketing and training materials to prepare for a launch.
The post IRRAS: Intracranial bleeding management device used on first U.S. patient appeared first on MassDevice.